SLC5A2 and type 2 diabetes mellitus: A meta-analysis of 15 randomized trials (with a total of 7,578 patients with type 2 diabetes mellitus) found an increase in total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, while a decrease in triglycerides with SGLT2 inhibitors compared to placebo or other oral glucose-lowering drugs.